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O. Sabri et al. / Alzheimer’s & Dementia 11 (2015) 964-974 965Abstract Background: Evaluation of brain b-amyloid by positron emission tomography (PET) imaging can
assist in the diagnosis of Alzheimer disease (AD) and other dementias.
Methods: Open-label, nonrandomized, multicenter, phase 3 study to validate the 18F-labeled b-am-
yloid tracer florbetaben by comparing in vivo PET imaging with post-mortem histopathology.
Results: Brain images and tissue from 74 deceased subjects (of 216 trial participants) were analyzed.
Forty-six of 47 neuritic b-amyloid-positive cases were read as PET positive, and 24 of 27 neuritic b-
amyloid plaque-negative cases were read as PET negative (sensitivity 97.9% [95% confidence inter-
val or CI 93.8–100%], specificity 88.9% [95% CI 77.0–100%]). In a subgroup, a regional tissue-scan
matched analysis was performed. In areas known to strongly accumulate b-amyloid plaques, sensi-
tivity and specificity were 82% to 90%, and 86% to 95%, respectively.
Conclusions: Florbetaben PET shows high sensitivity and specificity for the detection of
histopathology-confirmed neuritic b-amyloid plaques and may thus be a valuable adjunct to clinical
diagnosis, particularly for the exclusion of AD.
Trial registration: ClinicalTrials.gov NCT01020838.
 2015TheAuthors.PublishedbyElsevier Inc. onbehalf of theAlzheimer’sAssociation.This is anopen
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Amyloid; PET; Florbetaben; Histopathology1. Introduction
Progress in research to improve diagnostic accuracy and
treatment for Alzheimer disease (AD) depends on the char-
acterization of underlying pathophysiologic mechanisms
[1]. With estimates of more than a decade between the onset
of b-amyloid deposition and cognitive decline in affected in-
dividuals, the opportunity exists to introduce effective
disease-modifying regimens [2]. b-Amyloid imaging may
aid this process by facilitating early diagnosis.
The International Working Group for New Research
Criteria for the Diagnosis of AD recommends consideration
of a dual clinicobiological process for diagnosis, involving
the evidence of specific cognitive impairment together with
biomarkers [3]. The recommendation was recently updated
to categorize AD biomarkers according to whether they are
involved in pathology or progression [4]. As the amyloid
cascade is considered key to the pathogenesis of AD,
b-amyloid is one such biomarker; existing techniques
involve the imaging of b-amyloid plaques in the brain or
detection of decreased b-amyloid levels in cerebrospinal
fluid [5]. The successful use of such biomarkers has the po-
tential to improve screening and diagnosis of AD. Amyloid
imaging in particular is already being used as part of the eligi-
bility criteria in large, multicenter clinical therapeutic trials.
Several 18F-labeled b-amyloid ligands have been devel-
oped for positron emission tomography (PET) [6–9].
Phase 1 and 2 trials have been performed to study the
pharmacokinetics, safety, and diagnostic efficacy of
florbetaben [10–13]. Validating the accuracy of ante-
mortem assessment of brain b-amyloid load requires corre-
spondence between PETand histology-determined presence
of b-amyloid deposits. Such validation has not been
achieved to date because of technical challenges in ensuring
the assessment of identical regions by PET readers and pa-
thologists (for further details, see Supplemental Material).
A pivotal histopathology phase 3 study is reported here inwhich the in vivo binding of florbetaben to b-amyloid was
assessed by comparing whole-brain visual reads and quanti-
tative analysis with the final neuropathological diagnoses of
b-amyloid in the brain. In a subgroup, the visual assessment
of slices with tissue-matched regions of interest (ROIs) on
the PET scans was compared with the exact tissue-
matched post-mortem brain tissue.2. Methods
2.1. Study population
An international open-label, nonrandomized, multicenter
phase 3 study (ClinicalTrials.gov: NCT01020838) was con-
ducted in accordance with the Declaration of Helsinki. Ap-
provals by regulatory authorities and ethics committees
were obtained. Participants were recruited at 15 centers
(including dementia clinics with brain bank experience, hos-
pices, private practices, and dementia self-help groups) in
Australia, Europe, Asia, and North America, and examined
between February 2010 and July 2013. Patients with AD, de-
mentia with Lewy bodies (DLB), or other dementias, and
nondemented individuals, were included. Key exclusion
criteria included severe cerebral large-vessel disease, brain
tumors, and severe cardiovascular instability requiring inten-
sive care surveillance or therapeutic intervention.
Participants (or their legal representatives) provided writ-
ten informed consent to undergo brain magnetic resonance
imaging (MRI), a PET scan with florbetaben, and to donate
their brain for post-mortem examination. Participants
received compensation for expenses incurred (e.g., travel),
but no financial reward.
A cohort of young, cognitively normal healthy volunteers
(age, 22–38 years), considered highly likely to be b-amyloid
negative, was also recruited and studied by PET and MRI.
Volunteers provided written informed consent before study
procedures were carried out.
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PET imageswere acquired fromparticipants 90 to 110mi-
nutes after intravenous injection of 300 MBq6 20% florbe-
taben [14] according to a standardized acquisition and
image-processing protocol established during a technical
visit to each center. Three-dimensional volumetric T1-
weighted brain MRI data (e.g., magnetization prepared rapid
gradient echo or spoiled gradient recalled sequences) were
also collected.
2.3. Post-mortem brain histopathology
Brain samples from participants who died during the
study were used to determine the histopathology standard
of truth.
For whole-brain analysis, amyloid histopathology was
assessed according to the Consortium for Establishing a
Registry for Alzheimer Disease (CERAD) scores [15].
Tissue was regarded as positive when sufficient neuritic
plaques, detected by Bielschowsky silver staining, were
present to meet criteria for AD (CERAD score of
“frequent” or “moderate”). Histopathology was regarded
as negative when the CERAD score was “absent” or
“sparse.” Diffuse plaques do not contribute to the CERAD
score. The onsite pathologist conducted the autopsy (within
36 hours of death) and performed the CERAD scoring. In
the first 31 brains examined, six brain regions were addi-
tionally dissected (middle frontal gyrus, occipital cortex,
hippocampus/parahippocampal gyrus, anterior cingulate
cortex, posterior cingulate cortex/precuneus, and cerebellar
cortex). These regions were considered accessible for exact
removal and suitable for coregistration and direct correla-
tion of b-amyloid load as detected by in vivo PET imaging
and post-mortem histopathology. Brain removal, cutting,
block removal, photography, and embedding were per-
formed according to a predefined standardized procedure
(see Supplementary Material) to allow for alignment with
the MRI and PET image data. Samples were processed
for modified Bielschowsky silver staining [16] and immu-
nohistochemistry (IHC) for a beta with the monoclonal
6E10 antibody (Zytomed Systems, Berlin, Germany) (see
Supplementary Material) in a core laboratory. The same
tissue-section was then identified in MRI and PET images.
A section of up to 3.0! 2.5 cm was used for each area for
the histopathology assessment by a neuropathology
consensus panel (three neuropathology experts) to semi-
quantitatively determine the density of neuritic and diffuse
plaques separately as absent, sparse, moderate, or frequent
according to Mirra et al. [15].
For tissue-matched ROI analyses, an ROI was considered
positive if there were moderate neuritic/cored or diffuse
plaques, according to Bielschowsky silver staining or IHC.
Diffuse plaques were identified based on the morphological
appearance on either Bielschowsky silver staining or IHC
and scored in the same way as neuritic plaques (see
Supplementary Material).2.4. PET image processing
Full description ofMRI and PET image processing is pro-
vided in the Supplementary Material. Briefly, T1-weighted
volumetric MRI for each participant was aligned with the
photodocumented gross brain obtained at autopsy along
the sagittal plane for coregistration. As the macroscopic pa-
thology slices were cut at 1-cm intervals, the MRI was also
“sliced” at 1-cm intervals. The accuracy of MRI slicing was
compared against the photodocumented coronal pathology
slices and, after several iterations, made to align precisely.
Next, an ROI was drawn on the coronal MRI slices corre-
sponding to the exact tissue region removed post-mortem
for histopathological analysis. This was achieved by
comparing the MRI with the photodocumented coronal sli-
ces showing where the tissue block had been extracted.
Finally, the PET image was spatially normalized to the real-
ignedMRI, and 1-cm-thick coronal PET images correspond-
ing to the resliced MRI were obtained.2.5. PET image data assessment
The comparison of whole-brain pathology with whole-
brain imaging was made using a visual assessment method
proposed for routine clinical use, developed to be indepen-
dent of the availability of MRI scans. In a subgroup of par-
ticipants, comparisons were made between regional brain
pathology and tissue-matched ROIs placed on the PET scans
(for more information, see Supplementary Material).
PET images were assessed by three in-person trained, in-
dependent readers who were blinded to the clinical and his-
topathology results. Whole-brain visual assessment used
methodology adapted from previously described techniques
[10,12]. This involved a regional cortical tracer uptake
scoring system (1 5 no tracer uptake, 2 5 moderate tracer
uptake, 3 5 pronounced tracer uptake) in four brain areas,
with the resulting scores condensed into a binary
interpretation (score 1 5 negative; score 2 or
3 5 positive). In both whole-brain and tissue-matched ROI
analyses, visual assessments were compared with histopa-
thology results, and a majority-read approach was used to
calculate diagnostic efficacy.
For the whole-brain quantitative analysis, composite
cortical standardized uptake value ratios (SUVRs) were
determined as previously described [12], and receiver oper-
ating characteristic (ROC) curve analysis was used to ascer-
tain the optimal threshold for the sensitivity/specificity
calculation. The SUVR that provided the highest sum of
sensitivity and specificity as cutoff was determined.2.6. Statistical analyses
Two-sided 95% confidence intervals (CIs) were calcu-
lated [17]. Sensitivity and specificity (see Supplementary
Material) were evaluated using normal approximation with
95%CIs. Normal approximation/exact binomial distribution
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ificity of the whole-brain blinded read.
Inter- and intrareader agreements were estimated through
kappa coefficients [18]. Differences between demographic
parameters and SUVRs were tested using the independent
two-sample t-test for continuous variables, or Fisher exact
test for dichotomous variables. Correlations were calculated
using Spearman correlation coefficients with 95% CIs. Ana-
lyses of variance (ANOVAs) together with the Tukeymultiple
comparison test were used to investigate the association be-
tween the composite SUVRs and the CERAD scores. Unless
stated, all data are given as mean value6 standard deviation.3. Results
3.1. Study population
Of 253 individuals screened, 218 (86%) were enrolled
(Fig. 1), including 139 with a clinical diagnosis of AD, 5
with a clinical diagnosis of DLB, 31 with other dementias,
32 without dementia (primarily with oncological disorders),
and 11 young, cognitively normal volunteers.
In total, 216 participants underwent florbetaben injection
and PET imaging, including 205 end-of-life individuals (52%
male; mean age, 76.9 6 11 [range, 48–98] years) and 11
healthy volunteers. As of July 2013, 74 participants had died
(mean age 80.46 10.4 years; Supplementary Table 1) and un-
dergone autopsy and post-mortem histopathology. The cohort
included 57 patients with a clinical diagnosis of AD, 3 with
DLB, 6 with other dementias, and 8 without dementia. The
mean time from scan to death was 329 6 272 days
(Supplementary Table 1); 46 (62%) participants died within
1 year of the PET image being obtained, 20 (27%) within
2 years, and 8 (11%) after this time point. All 74 brains were
used in thewhole-brain analysis, and data from the first 31 par-
ticipants who died formed the tissue-matched ROI-analysis
subgroup. In addition, florbetaben PET data were analyzed
from 10 young cognitively normal volunteers (the remaining
volunteerwas excluded because of amajor protocol deviation).
3.2. Whole-brain analysis: Histopathology
The presence of neuritic b-amyloid plaques was
confirmed in 47 of the 74 participants using histopathology,
including only 44 of the 57 patients with a clinical diagnosis
of AD, 1 of the 3 patients with DLB, 1 of the 6 individuals
with “other” dementias, and 1 of the 8 individuals without
dementia. Of the 13 patients with a clinical diagnosis of
AD but no neuritic plaques, 12 had other neurodegenerative
pathologies and 1 had no pathologically relevant changes.
Overall, neuritic plaques were absent (i.e., “absent” or
“sparse” neuritic plaque CERAD score) in 27 participants,
including four with no neurodegenerative pathologies, and
23 with neurodegenerative pathologies other than AD
(e.g., Parkinson’s disease, Pick’s disease and other forms
of frontotemporal lobar degeneration, multisystem glial,
and neuronal tauopathy).3.3. Whole-brain analysis: Florbetaben PET
Scans were read as positive in 46 of the 47 cases with
positive Bielschowsky silver staining (i.e., with moderate
or frequent neuritic plaques on histopathology), and as
negative in 24 of the 27 cases with sparse or absent neuritic
plaques on histopathology. This resulted in a sensitivity of
97.9% (95% CI 93.8–100%) and a specificity of 88.9%
(95% CI 77.0–100%) for florbetaben PET in detecting/
excluding neuritic plaques (k 5 0.90 [95% CI 0.81–
0.98]) (Table 1). The negative and positive predictive
values for florbetaben PET were 96.0% (95% CI 88.3–
100%) and 93.9% (95% CI 87.2–100%), respectively. A
paradigmatic case with the brain regions to be assessed in
the whole-brain analysis is shown in Supplementary Fig.
1. All four patients without neurodegenerative pathologies,
and 20 of the 23 patients with non-AD neurodegenerative
pathologies, were read as florbetaben PET negative.
The whole-brain quantitative florbetaben PETassessment
included 73 scans; one was excluded because the MRI scan
was of insufficient quality for gray versus white matter seg-
mentation. Composite gray matter SUVRs were signifi-
cantly higher in patients with b-amyloid plaques versus
those without (1.716 0.27 vs 1.246 0.18; Fig. 2). ANOVA
correlation analysis between CERAD scores and composite
SUVRs found a highly significant (P , .00001) positive as-
sociation. Tukey multiple comparison test showed signifi-
cant differences in composite SUVRs between CERAD
groups as follows: composite SUVRsCERAD C . composite
SUVRsCERAD 0 (P , .00001), composite SUVRsCERAD
C . composite SUVRsCERAD A (P 5 .0004), composite
SUVRsCERAD B . composite SUVRsCERAD 0 (P 5 .033),
and composite SUVRsCERAD C . composite SUVRsCERAD
B (P 5 .035). ROC curve analysis of composite gray matter
SUVRs resulted in a cutoff that allowed the whole-brain
analysis group to be best separated into florbetaben-
positive or florbetaben-negative brains. This was achieved
with an SUVR of 1.478, resulting in a sensitivity of 89.4%
(95% CI, 80.6–98.2%) and a specificity of 92.3% (95% CI,
82.1–100%) to detect b-amyloid plaques via florbetaben
PET data quantification (Fig. 2).
3.4. Tissue-matched ROI analysis
Six ROIs matching the size and location of the six tissue
blocks assessed by pathologists were placed on each of the
scans from the first 31 patients who died. Similar ROIs
were placed on scans from the 10 healthy volunteers (consid-
ered to be amyloid negative) (Fig. 1). In total, 244 tissue-
matched ROIs were assessed, of which 106 were positive
for plaques on histopathology.
A high level of interreader agreement was achieved for all
brain ROIs (k5 0.66) (Supplementary Table 2). Eighty-two
of 106 ROIs were read as true PET positive, and 130 of 138
ROIs as true PET negative (Table 2; Fig. 3). In areas known
to show b-amyloid plaques more frequently in AD (i.e., fron-
tal cortex, anterior cingulate, posterior cingulate/precuneus
Fig. 1. Study flowchart of different trial stages. Two participants were enrolled but were not administered the positron emission tomography (PET) tracer as a
result of death or adverse event after study inclusion. Ten healthy volunteers whowere imagedwith florbetaben in this trial were included by considering them as
amyloid negative by definition. Tissue-matched region of interest (ROI) analysis was performed on a brain region-level basis considering central histopathology
assessment by Bielschowsky silver staining and b-amyloid immunohistochemistry (IHC) as standard of truth with the first 31 available post-mortem cases.
Whole-brain analysis was performed and compared against onsite histopathology assessment with the Consortium for Establishing a Registry for Alzheimer’s
Disease (CERAD) system as standard of truth in all 74 available post-mortem cases.
O. Sabri et al. / Alzheimer’s & Dementia 11 (2015) 964-974968area), tissue-matched ROI sensitivity was 82–90%, and
specificity was 86–95%. Sensitivity was lower (57%) but
specificity higher (100%) for the hippocampus, resulting in
an overall sensitivity of 77.4% (95% CI 65.3–89.4%) and
a specificity of 94.2% (95% CI 88.6–99.8%) for all ROIs.
In the tissue-matched ROI quantitative florbetaben PET
assessment, significantly higher SUVRs were found for re-
gions confirmed to have the histopathological evidence ofb-amyloid compared with regions that were scored negative
for b-amyloid, with the exception of the hippocampus/para-
hippocampal gyrus, consistent with the visual assessment
(Table 2; Supplementary Fig. 2).
Regional florbetaben SUVRs correlated significantly
with the consensus panel histopathology scores for neuritic
and diffuse plaques in the middle frontal gyrus (r 5 0.62
[95% CI 0.49–0.72]), occipital cortex (r 5 0.48 [95% CI
Table 1
Visual assessment of florbetaben PET images by three blinded readers in the
whole-brain analysis group (n 5 74)
Estimate 95% Lower CI 95% Upper CI
Sensitivity (%)
Majority read 97.9 93.8 100.0
Reader 1 97.9 93.8 100.0
Reader 2 100.0 92.5 100.0
Reader 3 97.9 93.8 100.0
Specificity (%)
Majority read 88.9 77.0 100.0
Reader 1 88.9 77.0 100.0
Reader 2 85.2 71.8 98.6
Reader 3 85.2 71.8 98.6
Abbreviations: PET, positron emission tomography; CERAD, Con-
sortium for Establishing a Registry for Alzheimer’s Disease; SUVRs, stan-
dardized uptake value ratios; CI, confidence interval.
NOTE. Onsite histopathology assessment by the CERAD criteria served
as standard of truth.
O. Sabri et al. / Alzheimer’s & Dementia 11 (2015) 964-974 9690.33–0.61]), anterior cingulate cortex (r 5 0.70 [95% CI
0.60–0.78]), and the posterior cingulate cortex/precuneus
(r 5 0.62 [95% CI 0.50–0.72]), but not in hippocampus/
parahippocampal gyrus (r 5 0.18 [95% CI 0.01–0.35]).
The respective box plots are provided in Supplementary
Fig. 3.
To determine the relationship between histopathologi-
cally determined plaque type and florbetaben uptake,
neocortical gray matter ROIs with b-amyloid histopathol-
ogy were considered: 21 with predominantly diffuse pla-
ques, and 60 with both diffuse and neuritic plaques. In
every instance, regions with neuritic plaques also had
diffuse plaque deposition. No significant florbetaben
SUVR differences were found between the two different
plaque types, whereas both groups had significantly
higher SUVRs compared with the plaque-negative ROIs
(Fig. 2).4. Discussion
Results from this study of florbetaben PET imaging to
detect b-amyloid deposits in the brains of individuals with
dementia demonstrate that the method used for the visual
assessment was reliable and suitable for use in clinical prac-
tice. Indeed, florbetaben has been approved in the EU and
USA in conjunction with a clinical evaluation, for PET im-
aging of b-amyloid neuritic plaque density in the brains of
adult patients who are being evaluated for AD and other
causes of cognitive impairment.
In the whole-brain analysis of 74 brains, the high
sensitivity and specificity associated with the visual anal-
ysis (97.9% and 88.9%, respectively) were consistent
with the sensitivity and specificity obtained using quanti-
tative assessment of the PET images (89.4% and 92.3%,
respectively). The sensitivity of the whole-brain analysis
was, however, substantially higher than that of the tissue-matched ROI analysis. This is due in part to the lack of
sensitivity in the hippocampus/parahippocampal gyrus.
This region contains gray and white matter within a rela-
tively small volume and is often atrophic, making it
prone to partial volume effects. These characteristics
made it difficult for the blinded imaging readers to prop-
erly assess this specific region. SUVR analysis for this
region corroborated this difficulty in assessment. Impor-
tantly, florbetaben PET imaging had a high negative pre-
dictive value (96.0%), indicating that a PET scan
evaluated as negative is a reliable indicator of the
absence of sufficient plaque pathology in the brain to
support a diagnosis of AD. In addition, the high positive
predictive value confirms that florbetaben PET provides a
reliable detection of plaques. It is important to note that
the presence of b-amyloid plaques alone is not sufficient
to diagnose AD, although cognitive impairment in the
presence of b-amyloid plaques is strongly suggestive of
AD. Consistent with previous studies, only 44 of 57
(77%) patients with a clinical diagnosis of AD in the
present study were actually found to have brain b-amy-
loid [21].
The tissue-matched ROI validation of this study is
the first direct, region-by-region anatomical comparison
of an 18F-labeled b-amyloid-targeted PET tracer uptake
with post-mortem histopathologically determined b-am-
yloid load in matched tissue sections and imaging
ROIs. In previous studies, in vivo versus post-mortem
b-amyloid signal association was established solely us-
ing whole-brain PET assessment [22,23], which
precluded detailed direct anatomic association between
tracer uptake and b-amyloid plaques. Furthermore,
PET data in previous studies were analyzed without
corresponding the assessment of individual brain
structural information provided by MRI. Our technique
for region matching in vivo PET data with post-
mortem histopathology data assured that identical brain
regions were evaluated by both PET and histopathology
readers, and that the gray matter was precisely separated
within the ROIs from the white matter, where b-amyloid
tracers are assumed to bind nonspecifically [24]. Hence,
this study method provides an exact tissue-matched
comparison of in vivo ROIs with post-mortem sections
for validating the accuracy of florbetaben binding to
b-amyloid.
Another advantage of this direct regional assessment of
PET and histopathology was to allow the analysis of the
ability of florbetaben to bind to diffuse and neuritic pla-
ques. Although there is growing evidence that all b-amy-
loid deposits add to the course of AD [25], and the
National Institute on Aging - Alzheimer’s Association
NIA-AA guidelines added nonneuritic b-amyloid deposi-
tion in form of modified Thal stages to the neuropatho-
logical assessment of AD [26], the binding of b-
amyloid imaging agents to diffuse plaques is controversial
and not well studied [27,28]. Here, we provide the largest
Fig. 2. Florbetaben uptake quantification in relation to brain plaque load and plaque types. (A) Boxplots of the composite standardized gray matter uptake value
ratios (SUVRs) of florbetaben positron emission tomography (PET) imaging in whole-brain analysis group subjects with and without b-amyloid plaques. Mean
SUVRs were compared against presence/absence of neuritic plaques as determined by onsite post-mortem histopathology according to Consortium for Estab-
lishing a Registry for Alzheimer’s Disease (CERAD) criteria. The boxes show median values and first (Q1) and third (Q3) quartiles. The whiskers represent Q1
6 1.5 of the interquartile ranges. (B) Receiver operating characteristic (ROC) curve for the composite gray matter SUVRs of florbetaben PET imaging in
discriminating between whole-brain analysis group subjects with and without b-amyloid plaques. The area under the ROC curve was 0.914. According to
this ROC statistics, the optimal separation SUVR threshold was determined as 1.48. Application of this cutoff SUVR resulted in a sensitivity and specificity
of 89.4% and 92.3% of florbetaben PET in detecting b-amyloid plaques. (C) The influence of the b-amyloid plaque type as detected by centralized post-mortem
histopathology using Bielschowsky silver staining and b-amyloid immunohistochemistry (IHC) in the tissue-matched gray matter region of interest (ROI) anal-
ysis group on the in vivo florbetaben uptake. Sixty ROIs exhibiting both diffuse and neuritic b-amyloid plaques were compared with 21 gray matter ROIs ex-
hibiting predominantly diffuse b-amyloid plaques and 41 gray matter ROIs without b-amyloid plaques. Ab, b-amyloid. (D) Florbetaben PET-positive case with
predominantly diffuse plaque pathology. Coronal T1 magnetization prepared rapid gradient echo magnetic resonance (MR) slice (upper left) at the level of the
posterior cingulate cortex/precuneus region of interest in which gray matter was segmented for gray matter PET analysis (blue box), corresponding coronal
florbetaben PET slice (upper right) with posterior cingulate cortex/precuneus volume of interest (blue box) which was rated by the blinded readers as positive
for cortical b-amyloid, corresponding post-mortem histopathology image of Bielschowsky silver staining (lower left) and IHC using monoclonal antibody 6E10
(lower right) predominantly exhibiting diffuse gray matter plaques. Black scale bars in histopathology images represent 200 mm.
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Table 2
Region-level visual and quantitative assessment of post-mortem tissue-matched florbetaben PET images (tissue-matched ROI analysis of 244 brain regions)
ROI (tissue matched)
Potential
b-amyloid load
Tissue-matched ROI visual assessment (majority read) Tissue-matched ROI quantitative assessment (SUVR)
b-Amyloid in histopathology
[TP/(TP 1 FN) (sensitivity
[95% CI])]
No b-amyloid in
histopathology [TN/(TN 1 FP)
(specificity [95% CI])]
b-Amyloid in histopathology
[mean6 SD (sensitivity [95% CI])*]
No b-amyloid in histopathology
(mean 6 SD (specificity [95%
CI])y]
SUVR difference
(95% CI)
Middle frontal gyrus Intense [19] 18/21 (85.7% [70.7–100%]) 19/20 (95.0% [85.4–100%]) 1.30 6 0.30** (90% [77.2–100%]) 0.95 6 0.12 (80% [62.5–97.5%]) 0.35 (0.20–0.51)
Occipital cortex Low [19] 16/18 (88.9% [74.4–100%]) 19/22 (86.4% [72.0–100%]) 1.34 6 0.27** (89% [74.5–100%]) 1.10 6 0.10 (67% [47.3–86.4%]) 0.23 (0.09–0.38)
Hippocampus/
parahippocampal
gyrus
Low; significant
atrophy [19,20]
12/21 (57.1% [36.0–78.3%]) 20/20 (100% [83.1–100%]) 0.99 6 0.21 (71% [51.6–90.4%]) 0.92 6 0.17 (60% [38.5–81.4%]) 0.07 (20.08–0.22)
Anterior cingulate
cortex
Intense [19] 18/20 (90.0% [77.0–100%]) 18/21 (85.7% [70.7–100%]) 1.36 6 0.26*** (80% [62.4–97.5%]) 0.96 6 0.15 (100% [83.9–100%]) 0.39 (0.24–0.54)
Posterior cingulate
cortex/precuneus
Intense [19] 18/22 (81.8% [65.7–98.0%]) 17/18 (94.4% [83.9–100%]) 1.49 6 0.35** (82% [66.0–98.0%]) 1.06 6 0.09 (100% [81.5–100%]) 0.43 (0.26–0.59)
Cerebellar cortex Reference [19] 0/4 (0.0% [0.0–60.2%]) 37/37 (100% [90.5–100%]) z z
All 82/106 (77.4% [65.3–89.4%]) 130/138 (94.2% [88.6–99.8%])
Abbreviations: PET, positron emission tomography; ROI, region of interest; FN, false negative; FP, false positive; CERAD, Consortium for Establishing a Registry for Alzheimer’s Disease; SUVR, standardized
gray matter uptake value ratio using the cerebellar cortex as reference region; TN, true negative; TP, true positive; CI, confidence interval.
NOTE. Centralized histopathology assessment using Bielschowsky silver staining and b-amyloid IHC served as the standard of truth. Column 2 describes knowledge from literature on the usual amount of
b-amyloid load in case of AD in the ROIs deliberately selected in this study to obtain a wide spectrum with different degrees of expected b-amyloid pathology. Group differences were tested for significance using
the t-test for independent samples.
*P , .05; **P , .01; ***P , .001 vs “no b-amyloid histopathology.”
yDerived from receiver operating characteristic curve analyses.
zReference region for SUVR calculation.
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Fig. 3. Two paradigmatic tissue-matched region of interest (ROI) analysis examples. The upper row shows results from a b-amyloid-positive patient
(Case 48) and the lower row shows findings from a b-amyloid-negative patient (Case 45). Coronal T1 magnetization prepared rapid gradient echo mag-
netic resonance (MR) slices at the level of the posterior cingulate cortex/precuneus ROI (A, E), corresponding coronal florbetaben positron emission
tomography (PET) slices (B, F), corresponding post-mortem coronal brain slice photodocumentation (C, G), and corresponding histopathology images
(black scale bars representing 200 mm) of Bielschowsky silver staining (D, H). Based on the photodocumented size and position of the posterior cingulate
cortex/precuneus brain blocks, which were removed post-mortem, respective ROIs were defined on the individual in vivo MRI and coregistered florbe-
taben PET imaging data (blue boxes). Note that PET/MRI versus brain slice coregistration was optimized toward the ROI, as it was not possible to
perfectly fit all brain parts in the respective slices due to post-mortem brain shrinkage and deformation. Within the ROIs, the gray matter was segmented
for tracer uptake analysis. In concordance with the results of the Bielschowsky silver staining that revealed plaque positivity (D) and negativity (H),
cortical florbetaben uptake was evident (B), and absent (F).
O. Sabri et al. / Alzheimer’s & Dementia 11 (2015) 964-974972set of brain sections with an appropriate methodology to
confirm that florbetaben binds to both neuritic and diffuse
plaques in vivo.
One limitation of the study, which is also applicable to
other comparisons of in vivo b-amyloid PET imaging with
post-mortem histopathology [22,23], is that clinical
features of end-of-life individuals had significant end-
stage medical illnesses that could bias the PET data. For
example, some patients had pronounced brain atrophy,
which made visual assessment of the PET scans chal-
lenging, negatively biasing the association between
the PET and histopathology signals. Furthermore, the pos-
sibility cannot be excluded that the pharmacodynamics
and pharmacokinetics of b-amyloid-targeted PET tracers
are different in end-of-life patients compared with earlier
stage patients in whom PET has greater clinical relevance
and in whom future clinical application is desired. If b-
amyloid PET imaging is to be used routinely in the
clinical assessment of such patients, then there is a need
for large-scale controlled diagnostic trials in patients in
the early stages of dementia [12]. Only such studies,
together with pivotal in vivo PET versus post-mortem his-
topathology comparisons as carried out in the present
study, will provide the full picture of the clinical efficacy
of b-amyloid PET imaging as an adjunct to clinical
assessment for early, ante-mortem diagnosis of AD and
prodromal AD.In conclusion, high sensitivity and specificity, and high
predictive values for florbetaben PET, were confirmed by
histopathology in clinically relevant whole-brain visual ana-
lyses, allowing the reliable detection and exclusion of amy-
loid pathology. Moreover, this study involved the rigorous
validation of florbetaben PET in an exact tissue-matched
ROI analysis. These data, together with the results from
earlier studies [10–12,14,29–31], support the value of
florbetaben PET as a diagnostic marker, particularly as a
valuable adjunct for the exclusion of AD or differential
diagnosis of dementia.Acknowledgments
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1. Systematic review: Only one clinical trial with two
publications [22,23] is reported in PubMed
comparing an 18F-labeled b-amyloid agent against
autopsy-derived histopathology.
2. Interpretation: In our study, which is the second to be
reported meeting the aforementioned criteria, florbe-
taben positron emission tomography (PET) was
investigated in a global phase 3 trial. A high diag-
nostic efficacy was determined for the detection of
neuritic plaques in 74 deceased subjects. In a sub-
group, an exact tissue-scan matched analysis was
performed in 244 samples. As such, it is the first trial
to directly compare PET regions ante-mortem to
identical tissue regions analyzed post-mortem.
Florbetaben PET confirmed efficacy for the in vivo
detection of b-amyloid deposits, both on a whole
brain and on a regional brain level.
3. Future directions: Trials testing b-amyloid PET in
the early dementia stage are needed and the influence
of plaque morphology on the PET signal needs to be
further explored.References
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